Paul Bresge
CEO / Co-Founder
Ray Therapeutics, Inc.
This company develops small molecule drugs targeting immunological pathways to treat diseases with unmet medical needs. They aim to create transformative therapies that offer improved treatment options for patients with immunological disorders.
- Biotechnology
Updated 17 months ago
Funding
Raised to date
$8MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Many immunological diseases lack effective and safe treatments, leaving a significant unmet medical need for patients suffering from these conditions. Current therapies often have limited efficacy or are associated with significant side effects, highlighting the need for novel therapeutic approaches.
Solution
RayThera is a drug discovery company focused on developing breakthrough small molecule therapies for immunological diseases. By leveraging their expertise in drug discovery and a nimble approach, RayThera aims to accelerate the development of safer and more effective therapeutics. Their focus is on preclinical and early drug discovery, with the goal of delivering innovative solutions that can transform patient care in immunology.
Target Audience
The primary target audience includes patients with immunological diseases who are seeking safer and more effective treatment options.
Features
- Specializes in small molecule therapies targeting immunological pathways.
- Focuses on preclinical and early-stage drug discovery.
- Employs a nimble and adaptable approach to accelerate drug development.